Streetbeat News

Stock Prices

BTCUSD

Crypto analyst Michaël van de Poppe dismisses fears of a major Bitcoin crash, viewing the recent 26% price correction as normal. He anticipates a bull run for Bitcoin until 2026, despite current market downturns and economic concerns.

Portfolio Pulse from Aniket Verma

September 09, 2024 | 8:35 am

MSFT

NVDA

Despite the AI-driven rally in stocks like Nvidia and Microsoft, the tech sector faces underlying weaknesses, with many companies struggling post-recession. Non-AI tech firms are experiencing slow growth or contraction, and investor enthusiasm for AI stocks has waned.

Portfolio Pulse from Benzinga Neuro

September 09, 2024 | 8:24 am

AMZN

AVO

GOOG

GOOGL

MTRX

NVDA

ORCL

The S&P 500 experienced its largest weekly decline since March 2023, driven by a sell-off in megacap tech stocks like Amazon, Alphabet, and NVIDIA. The CNN Money Fear and Greed index shifted to the 'Fear' zone, indicating declining market sentiment. Despite a positive jobs report, most sectors closed negatively, with real estate being an exception.

Portfolio Pulse from Avi Kapoor

September 09, 2024 | 8:13 am

DSNKY

MRK

Daiichi Sankyo and Merck's drug, ifinatamab deruxtecan, shows a 54.8% response rate in a Phase 2 trial for small cell lung cancer, with 12 mg/kg chosen as the optimal dose for further studies.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 8:13 am

AVO

BKSY

HYZN

MTRX

ORCL

U.S. stock futures are trading higher, with Oracle, BlackSky Technology, Mission Produce, Hyzon Motors, and Matrix Service being key stocks to watch. Oracle and Mission Produce are set to report earnings, while BlackSky surged due to a NASA award. Hyzon announced a reverse stock split.

Portfolio Pulse from Avi Kapoor

September 09, 2024 | 8:10 am

TSLA

Elon Musk denied reports of a revenue-sharing deal between Tesla and his AI startup xAI. He stated that Tesla has benefited from discussions with xAI engineers but does not need to license xAI's technology. The Wall Street Journal had reported potential licensing and revenue-sharing agreements between the two companies.

Portfolio Pulse from Anan Ashraf

September 09, 2024 | 8:06 am

AZN

AstraZeneca and Daiichi Sankyo's drug, Datopotamab Deruxtecan, showed significant improvement in progression-free survival for non-small cell lung cancer patients with the TROP2 biomarker in the TROPION-Lung01 Phase 3 trial.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 8:04 am

EMCG

Embrace Change has received a warning from Nasdaq due to a delay in filing its quarterly report. The company plans to submit the report by the end of September.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 8:01 am

AAPL

Apple is set to launch the iPhone 16, which could trigger the biggest upgrade cycle in its history, according to Wedbush analyst Dan Ives. The integration of AI is expected to drive this supercycle, with initial shipments projected to exceed expectations. Ives maintains an outperform rating on Apple stock with a price target of $285.

Portfolio Pulse from Kaustubh Bagalkote

September 09, 2024 | 7:54 am

LBPH

Longboard Pharmaceuticals reported interim results from its Phase 1b/2a PACIFIC study, showing a 57.7% reduction in seizures for DEE patients treated with Bexicaserin. The drug demonstrated favorable safety and tolerability. Full data is expected early next year.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 7:51 am